Cancer Therapy-Related Cardiovascular Toxicity (CTR-CVT)
Definition
CTR-CVT encompasses the full spectrum of cardiovascular complications that arise directly or indirectly from cancer therapy — chemotherapy, targeted agents, immune therapies and radiation. CTRCD (cancer therapy-related cardiac dysfunction) is the subset comprising cardiomyopathy and heart failure, and captures both the range of presentations and the aetiological link with anticancer treatment. CTR-CVT risk is a dynamic variable across the cancer care continuum (before, during and after treatment): absolute risk depends on baseline patient risk and on cumulative exposure to cardiotoxic therapy over time (sources/Cardio-Oncology-ESC-2022, rating: very high).
This page covers the clinical pathway — risk stratification, surveillance, prevention, management and drug-specific profiles. Arrhythmia, autonomic dysfunction, hormonal therapy, cancer-associated VTE, clonal haematopoiesis and AI/multi-omics have dedicated pages, linked under Topics on dedicated pages.
Key Concepts
Epidemiology and incidence
- Cancer and cardiovascular disease are the two leading causes of mortality in developed countries; falling cancer mortality since the 1990s has produced a growing survivor population with a rising CTR-CVT burden (sources/Cardio-Oncology-ESC-2022, rating: very high).
- Incidence is agent-specific and often dose-dependent; the figure used for each class is stated here once.
| Therapeutic class | Principal CV toxicity | Incidence | Comment |
|---|---|---|---|
| Anthracyclines | CTRCD | Dose-dependent and cumulative; risk rises above 250 mg/m² doxorubicin-equivalent | Irreversible myocardial injury |
| HER2-targeted (trastuzumab, pertuzumab, T-DM1) | LV dysfunction | 15–20% | Usually reversible on stopping |
| VEGF inhibitors | Hypertension | 20–80% (class effect); >50% with newer agents; pazopanib 57% in treatment-naïve mRCC | Salt-dependent; see VEGF inhibitor hypertension |
| Fluoropyrimidines (5-FU, capecitabine) | Myocardial ischaemia | Up to 10%; 5.4% with continuous 5-FU | Coronary vasospasm plus endothelial injury |
| Immune checkpoint inhibitors | Myocarditis | 0.1–1.1%, fatality 25–50% | Most within the first 12 weeks |
| CAR-T / TIL | CRS-related injury | Arrhythmia 77.6%, HF 14.3%, MI/VTE ~0.5% of CRS-affected patients | High mortality in fulminant CRS |
| BTK inhibitors (ibrutinib) | AF, hypertension | AF 3–16%; new hypertension 71.6% of normotensive patients; VA risk 12× | Ibrutinib carries the highest burden of any targeted agent; generation-dependent |
| BCR-ABL TKIs | PAH, arterial occlusion | Dasatinib PAH 5% vs 0.4% with imatinib (DASISION); nilotinib and ponatinib arterial occlusive events | Ponatinib carries an FDA boxed warning |
| Multiple myeloma therapies | HF, hypertension, VTE | Carfilzomib HF/CTRCD; IMiDs VTE and bradyarrhythmia | Cardiac AL amyloidosis places the patient in the very-high-risk HFA-ICOS group |
| Radiotherapy | CAD, valvular, pericardial, conduction, cardiomyopathy | Risk banded by mean heart dose | >25 Gy very high risk |
Figures are from the ESC 2022 guideline (sources/Cardio-Oncology-ESC-2022, rating: very high) unless the row names another source; BTK generation-specific figures are from the 2025 ACC clinical guidance (sources/cancer-rx-cv-acc-2025). Classes whose burden is defined mainly by a monitoring schedule rather than a headline incidence — RAF/MEK and CDK4/6 inhibitors, EGFR TKIs, HSCT and endocrine therapy — are given with their rates in the drug-profile tables below.
Baseline risk stratification — HFA-ICOS
- The HFA-ICOS tool (Class IIa/C) sorts patients into Low / Moderate / High / Very High baseline risk before potentially cardiotoxic therapy, applied separately for anthracyclines, HER2-targeted therapy, VEGF inhibitors, BCR-ABL TKIs, myeloma therapies and RAF/MEK inhibitors (sources/Cardio-Oncology-ESC-2022, rating: very high).
- Very High = any single VH factor (e.g. pre-existing HF, cardiomyopathy or CTRCD). High = any single H factor (LVEF <50%, age ≥80, prior mediastinal radiotherapy, prior anthracycline, severe valvular disease, prior MI/PCI/CABG). Moderate = 2–4 points from scored factors (M1 = 1 point, M2 = 2 points); ≥5 points is High. Low = no factors, or one M1 factor.
- Actions by level: Low, proceed without delay; Moderate, consider cardiology referral (IIb); High/VH, cardiology referral before starting treatment (I) plus MDT discussion (I) and cardioprotective strategies (IIa). The result must be documented and communicated to the patient (I).
- Full scoring by treatment category, anthracycline equivalence ratios and dose thresholds: concepts/HFA-ICOS-Risk-Stratification.
CTRCD severity classification
The grade determines management in every agent-specific section below (sources/Cardio-Oncology-ESC-2022, rating: very high).
| Category | Definition |
|---|---|
| Symptomatic — mild | HF symptoms without need to intensify HF therapy |
| Symptomatic — moderate | Outpatient intensification of diuretic or HF therapy |
| Symptomatic — severe | HF hospitalisation |
| Symptomatic — very severe | Inotropes, mechanical circulatory support, or transplant assessment |
| Asymptomatic — mild | LVEF ≥50% with new relative GLS decline >15% and/or new biomarker rise |
| Asymptomatic — moderate | New LVEF reduction ≥10 percentage points to LVEF 40–49%; or reduction <10 points to 40–49% with GLS decline >15% or biomarker rise |
| Asymptomatic — severe | New LVEF reduction to <40% |
Diagnosis and surveillance
- Baseline: 12-lead ECG in all patients starting cancer therapy (Class I); 3D echocardiography with GLS for high/VH risk (I); cTn plus natriuretic peptide in all patients in whom biomarkers will be tracked during treatment (I) (sources/Cardio-Oncology-ESC-2022, rating: very high).
- Same imaging modality and the same vendor throughout treatment — mandatory, to avoid inter-technique and inter-vendor variability (I).
- GLS threshold: a relative decline >15% from baseline defines asymptomatic mild CTRCD, chosen to maximise specificity and limit overdiagnosis; an absolute GLS <16% also contributes to risk classification.
- Biomarkers have no cancer-specific reference values. Interpret against treatment timing, comorbidity, age, sex, renal function, obesity, AF and pulmonary embolism.
- CMR when echocardiography is unavailable or non-diagnostic (including fast strain-encoded CMR where available); MUGA is third-line only. Image at any time if new cardiac symptoms develop.
- ICI myocarditis is diagnosed pathologically (endomyocardial biopsy showing multifocal inflammatory infiltrate with cardiomyocyte loss) or clinically (cTn elevation plus ≥1 major criterion — a CMR diagnostic of myocarditis — or ≥2 minor criteria, after excluding ACS) (sources/Cardio-Oncology-ESC-2022). CMR LGE and T2-STIR are diagnostic; native T1 elevation predicts MACE (n=136), and serial hsTnI detects both symptomatic and asymptomatic cases (sources/ai-cardiooncology-aha-2025, rating: high).
Imaging (AHA 2023 framework)
The AHA 2023 statement moves beyond LVEF to a multimodal framework mapped by therapy type and by clinical presentation (sources/imaging-cardio-oncology-aha-2024, rating: high).
- Echocardiography is first-line for all patients: 3D acquisition for LVEF, RV function at baseline, and GLS with the thresholds above — absolute <16% or relative decline >15% triggers closer surveillance and possible cardioprotection even when LVEF ≥53%. In SUCCOUR strain-guided therapy did not improve the LVEF endpoint, so strain is most useful when LVEF is low-normal. Routine echocardiography is not required for ICI therapy unless HF symptoms or myocarditis are suspected.
- CMR is second-line: poor sonographic windows, borderline or abnormal LVEF, complex differentials (toxic vs ischaemic vs inflammatory), suspected myocarditis, ventricular arrhythmia and scar quantification. T1/T2 mapping is diagnostic and prognostic in ICI myocarditis, and native T1 and ECV capture fibrotic change across agents.
- Cardiac CT adds coronary calcium scoring to re-stratify ASCVD risk in survivors (statin therapy is underused when CAC is found incidentally on staging CT); CCTA has a very high negative predictive value for the ACS mimickers of fluoropyrimidines and ICI and is preferred over invasive angiography when bleeding risk is high; it also supports valve planning and LVEF assessment when echo and CMR are unavailable.
- Nuclear imaging: MUGA remains third-line; ⁹⁹mTc-PYP SPECT has strong evidence for suspected transthyretin amyloidosis (concepts/Cardiac-Amyloidosis-Imaging); FDG-PET did not differentiate ICI myocarditis outcomes but helps correlate tumour burden with CAR-T CRS; ⁶⁸Ga-DOTATOC and ⁶⁸Ga-FAPI are promising in small series only.
| Therapy | Echo | CMR | CCT | Nuclear | Key guidance |
|---|---|---|---|---|---|
| Anthracyclines | +++ | ++ | − | − | Baseline if ≥1 risk factor; repeat during treatment; surveillance every 2–5 years after |
| HER2-targeted | +++ | ++ | − | − | As anthracyclines |
| ICI | +++ | +++ | ++ | ++ | Baseline if ≥1 risk factor; repeat if toxicity suspected |
| CAR-T | +++ | ++ | + | − | Baseline if ≥1 risk factor; echo or CMR within 12 months |
| BTK inhibitors | +++ | ++ | − | − | Baseline if ≥1 risk factor; after treatment if toxicity suspected |
| VEGF inhibitors | ++ | + | + | + | Baseline if ≥1 risk factor; after treatment if toxicity suspected |
| Fluoropyrimidines | ++ | + | ++ | + | CCT, nuclear, CMR or PET if ACS suspected |
| Radiation | +++ | + | ++ | ++ | Baseline; CCT, nuclear or CMR if ACS suspected after treatment |
| Presentation | Echo | CMR | CCT | SPECT | PET |
|---|---|---|---|---|---|
| Heart failure | +++ | ++ | + | ++ | + |
| ACS | +++ | ++ | +++ | +++ | +++ |
| Ventricular arrhythmia | +++ | +++ | + | − | − |
| Myocarditis | +++ | +++ | + | − | + |
| Cardiac amyloidosis | +++ | +++ | − | +++ | − |
| Pericarditis | +++ | ++ | + | − | − |
| Atrial fibrillation / SVT | +++ | + | + | − | − |
- Disparities: Black patients with breast cancer have 4.61× higher cardiotoxicity causing incomplete HER2 therapy; Black individuals and women have a 3-fold increase in ICI-related cardiac events, and childhood cancer survivors an RR of 1.68; Medicare data show lower transthoracic echocardiography use in Black women (RR 0.92). Dedicated cardio-oncology referral with serial imaging may mitigate this.
- Paediatric patients: over 50% of children with cancer receive cardiotoxic therapy. Echocardiography should use a segmental approach including extracardiac anatomical relationships; CT and PET should minimise radiation and contrast; CMR-biomarker correlation after anthracyclines has been shown prospectively.
Prevention
Primary prevention (sources/Cardio-Oncology-ESC-2022, rating: very high)
- Cancer and CVD share modifiable risk factors. Optimise smoking, alcohol (≤100 g/week) and physical activity, and treat hypertension, diabetes and dyslipidaemia before and during treatment without delaying cancer therapy (Class I/C). Correct hypokalaemia and hypomagnesaemia throughout.
- Dexrazoxane (iron chelator, Class IIa/B) for high/VH risk receiving anthracyclines: 10:1 ratio (500 mg/m² per 50 mg/m² doxorubicin), infused ≥30 minutes before each cycle. Thresholds for use differ: EMA ≥350 mg/m², FDA ≥300 mg/m² doxorubicin-equivalent.
- Liposomal anthracyclines (pegylated and non-pegylated) are less cardiotoxic than conventional doxorubicin in a meta-analysis of 19 trials — Class IIa/B for high/VH risk.
- ACE-I/ARB plus beta-blocker at HF doses: Class IIa/B for anthracyclines and/or anti-HER2 therapy; Class IIa/C for VEGF inhibitors, bevacizumab, RAF/MEK inhibitors, proteasome inhibitors, dasatinib, ponatinib and osimertinib. Carvedilol is preferred; bisoprolol, metoprolol succinate and nebivolol are alternatives.
- Statins: Class IIa/B for adults at high/VH cardiotoxicity risk by HFA-ICOS.
- Radiotherapy: heart-sparing techniques (intensity-modulated RT, deep-inspiration breath-hold, proton therapy) reduce mean heart dose. No drug prophylaxis is proven; control of cardiovascular risk factors is the cornerstone.
Secondary prevention — for pre-existing CVD (including prior CTR-CVT) and for new CTR-CVT during therapy
- Optimal guideline-based treatment of CVD and comorbidities before and during cancer treatment, without delaying it (Class I/C).
- Regular clinical assessment, 12-lead ECG, echocardiography and biomarkers; frequency set by baseline risk and by the emergence of new CTR-CVT.
Management of CTRCD
Anthracyclines (sources/Cardio-Oncology-ESC-2022, rating: very high)
| Severity | Action | Class |
|---|---|---|
| Severe symptomatic | Discontinue; rechallenge only through MDT | I/C |
| Moderate symptomatic | Interrupt; MDT restart after LV recovery | I/C |
| Mild symptomatic | MDT decision to interrupt or continue | I/C |
| Severe asymptomatic (LVEF <40%) | Interrupt plus full HF therapy: ACE-I/ARNi + beta-blocker + SGLT2 inhibitor + MRA | I/C |
| Moderate asymptomatic (LVEF 40–49%) | Interrupt plus HF therapy | I/C |
| Mild asymptomatic (LVEF ≥50% with GLS decline >15% and/or biomarker rise) | Continue plus ACE-I/ARB ± beta-blocker | IIa/B for GLS decline or troponin rise; IIb/C for NP rise alone |
Rechallenge, when pursued, uses dose minimisation, a switch to liposomal anthracycline (IIb/C), pre-treatment dexrazoxane (IIb/C), and monitoring every 1–2 cycles.
HER2-targeted therapy
| Severity | Action | Class |
|---|---|---|
| Moderate–severe symptomatic | Interrupt plus HF therapy | I |
| Moderate asymptomatic (LVEF 40–49%) | Continue HER2 therapy plus ACE-I/ARB + beta-blocker and frequent monitoring | IIa/B |
| Mild asymptomatic (LVEF ≥50% with GLS decline or biomarker rise) | Continue and consider ACE-I/ARB ± beta-blocker | IIa/B |
Continuing rather than interrupting for asymptomatic moderate dysfunction is a departure from earlier guidance, which mandated interruption. Restart after interruption when LVEF ≥40% and the patient is asymptomatic, with echo and biomarkers every 2 cycles for 4 cycles, then less often.
End-of-therapy weaning
- Full recovery means no HF symptoms, LVEF >50%, and GLS and biomarkers normal or back to baseline.
- Low risk for weaning (IIa): low or moderate baseline risk, a reversible agent (e.g. trastuzumab alone), mild CTRCD, recovery within 3–6 months, and no family history of cardiomyopathy.
- Continue long-term HF therapy (I): severe or very severe CTRCD, incomplete LV recovery, high baseline risk, an irreversible agent, or a family history of cardiomyopathy. Reassess echocardiography and biomarkers after any withdrawal.
- End-of-treatment assessment within 1 year of completing cardiotoxic therapy (I for all); surveillance echocardiography at years 1, 3 and 5, then every 5 years for high/VH risk.
ICI myocarditis
- Interrupt the checkpoint inhibitor for every suspected case; confirmed myocarditis means permanent cessation (Class I/C) (sources/Cardio-Oncology-ESC-2022, rating: very high).
- Classify as fulminant (haemodynamic instability, HF requiring ventilation, complete AV block, significant ventricular arrhythmia), non-fulminant, or steroid-refractory (worsening despite high-dose methylprednisolone) (sources/cancer-rx-cv-acc-2025, rating: very high).
- Methylprednisolone 1,000 mg IV daily for 3 days, then oral prednisolone 1 mg/kg/day once improving, weaned by about 10 mg/week over 5 weeks (sources/cancer-rx-cv-acc-2025).
- Steroid-refractory disease: mycophenolate mofetil, tacrolimus, ruxolitinib, abatacept, plasmapheresis, alemtuzumab, antithymocyte globulin or IVIG. Infliximab should be avoided — it exacerbates HF in patients with myocarditis.
- Fulminant disease: ICU, IV methylprednisolone and optimal cardiovascular support including mechanical circulatory support (I/C); early additional immunosuppression is critical.
- Upfront targeted immunomodulation (Salem et al.) — abatacept plus ruxolitinib achieved 3.4% mortality versus 60% in a historical steroid-only control; this is a prospective observational comparison and randomised trials are awaited.
- Early detection without cardiac tests: rises in CPK, AST, ALT or LDH precede clinical presentation by about 20 days; CPK has 99% sensitivity but only 23% specificity, and normal values across all four make significant myocarditis unlikely. cTnT <2× ULN (28 ng/L) is usually benign, a more than 2-fold rise precedes myocarditis in about one third, and a peak above 32× ULN carries 9× MACE risk at 100 days (sources/cancer-rx-cv-acc-2025).
- Rechallenge: NCCN and ASCO advise permanent discontinuation for grade ≥2 toxicity; case-by-case rechallenge may be considered for low-severity disease with no oncological alternative.
Other cardiovascular complications
Coronary artery disease (sources/Cardio-Oncology-ESC-2022, rating: very high)
- Mechanisms split into accelerated atherosclerosis (ADT, ICI, nilotinib, ponatinib, radiotherapy, VEGF inhibitors), vasospasm (bleomycin, fluoropyrimidines, taxanes, vinca alkaloids) and coronary thrombosis (cisplatin, cyclophosphamide, erlotinib, ICI, IMiDs).
- An invasive strategy is indicated for STEMI and high-risk NSTE-ACS when life expectancy is ≥6 months (Class I/B), and a conservative strategy is reasonable below 6 months (IIa/C).
- DAPT with aspirin and clopidogrel, kept short (1–3 months). Antiplatelet thresholds in thrombocytopenia are given under Practical thresholds and drug interactions.
Pericardial disease
- Causes include radiotherapy, anthracyclines, bleomycin, cyclophosphamide, cytarabine, dasatinib, ICI and all-trans retinoic acid; differentiate from cancer progression and infection.
- ICI pericarditis has a median onset of 30 days; severe cases need ICI discontinuation plus methylprednisolone 1 mg/kg/day ± colchicine (I/C).
- Malignant effusion accounts for >30% of tamponade cases. Use echo-guided pericardiocentesis for tamponade and a surgical window for recurrence (IIa/C).
Pulmonary hypertension
- All five WHO groups occur in cancer. For dasatinib-associated PAH, a peak TRV >3.4 m/s warrants right heart catheterisation and drug discontinuation (I/C); TRV 2.9–3.4 m/s warrants dose reduction with echocardiography every 4 weeks (IIa/C), switching TKI once TRV recovers.
Drug profiles — cytotoxic chemotherapy
Monitoring intervals and classes are from the ESC 2022 guideline (sources/Cardio-Oncology-ESC-2022, rating: very high).
| Agent | Principal toxicity | Monitoring | Prevention and notes |
|---|---|---|---|
| Anthracyclines | CTRCD — dose-dependent and irreversible | Baseline TTE with GLS (I/B) and cTn + NP (I/B, high/VH); TTE every 2 cycles and within 3 months (I/C, high/VH); cTn + NP before every cycle (I/B, high/VH) or every 2 cycles (IIa/C, moderate); extra TTE after cumulative ≥250 mg/m² (IIa/C, moderate); TTE within 12 months of completion (I/B, all) | Dexrazoxane or liposomal formulation; ACE-I + carvedilol (IIa/B, high/VH) |
| HER2-targeted (trastuzumab, pertuzumab, T-DM1) | LV dysfunction in 15–20%, usually reversible; risk much higher with concurrent anthracycline, so sequential use is preferred | Baseline TTE (I/B); every 3 months during neoadjuvant/adjuvant treatment (I/B) or metastatic year 1 (I/C); every 4 months if low risk and normal at 3 months (IIb/C); baseline cTn after anthracycline and before trastuzumab (IIa/A) | Continue rather than interrupt for asymptomatic moderate CTRCD; restart when LVEF ≥40% |
| Fluoropyrimidines (5-FU, capecitabine) | Angina, ischaemia, Takotsubo, MI with normal coronaries, myocarditis, arrhythmia, hypertension; ischaemia up to 10% | CV risk assessment plus ECG, lipid profile and HbA1c (I/C); baseline TTE if known CVD (I/C) | Rechallenge after vasospasm is controversial — monitored unit, long-acting nitrate and CCB prophylaxis, only after excluding severe CAD |
Drug profiles — targeted kinase inhibitors
| Agent | Principal toxicity | Monitoring | Prevention and notes |
|---|---|---|---|
| VEGF inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib) | Hypertension 20–80%; arterial and venous thromboembolism; CTRCD; QTc prolongation (sunitinib, sorafenib, vandetanib) | Home BP daily through the first cycle and after dose increases (I/C); QTc monthly for 3 months then every 3–6 months if at risk (I/C); TTE every 3 months in year 1 (IIa/C, high/VH) or every 4 months (IIb/C, moderate) | ACE-I/ARB plus amlodipine; avoid non-DHP CCBs; reduce antihypertensives when the VEGF inhibitor stops |
| BCR-ABL TKIs (imatinib, dasatinib, nilotinib, ponatinib) | Dasatinib: PAH (5%), pleural and pericardial effusion, HF. Nilotinib and ponatinib: arterial occlusive events, PAD, MI. QTc prolongation | Baseline CV risk assessment (I/C) and every 3 months in year 1 (I/C); dasatinib baseline TTE (I/C) and every 3 months in year 1 if high/VH (IIa/C); nilotinib QTc at baseline, 2 and 4 weeks and after dose increases (IIa/C) with serial lipids and HbA1c; ponatinib serial ankle-brachial index (IIb/C) | Ponatinib carries an FDA boxed warning for arterial occlusion — antiplatelet plus statin and heightened surveillance |
| BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) | AF — ibrutinib 3–16%, acalabrutinib 4–9%, zanubrutinib 3–6%, pirtobrutinib 3.2%; hypertension — new in 71.6% and worsening in 82.4% of ibrutinib-treated patients, >160/100 in up to 18%, acalabrutinib 59%, zanubrutinib 5–11%; ventricular arrhythmia 12×; HF ROR 3.5 (VigiBase). Acalabrutinib has fewer symptomatic CV events but comparable grade ≥3 AF in older patients and those with prior AF | BP every visit plus home monitoring; ECG every 3 months in year 1 then every 3–6 months; opportunistic AF screening (sources/cancer-rx-cv-acc-2025) | Beta-blocker rate control; factor Xa inhibitor preferred; avoid dabigatran, non-DHP CCBs and amiodarone; switch to a second- or third-generation agent |
| RAF/MEK inhibitors (vemurafenib, trametinib, cobimetinib) | QTc prolongation; CTRCD (1 month to 2 years); hypertension; peripheral vascular disease | BP every visit plus weekly home monitoring for 3 months (I/C); ECG at 2 and 4 weeks then every 3 months (I/C); TTE every 4 months in year 1 if high/VH (IIa/C) | |
| CDK4/6 inhibitors (ribociclib, palbociclib, abemaciclib) | QTc prolongation (ribociclib mainly); neutropenia as an indirect CV risk | QTc at baseline, day 14 and day 28 (I/A), repeated with any dose increase (I/B) | Interrupt if QTcF >480 ms (EMA) |
| EGFR TKIs (osimertinib) | QTc prolongation; CTRCD; hypomagnesaemia amplifying QTc | Baseline TTE and ECG (I/B); TTE every 3 months (IIa/B) | Monitor magnesium closely |
Drug profiles — immune, cellular and transplant therapies
The checkpoint inhibitor data are from the ESC guideline unless stated otherwise; see ICI myocarditis for full management.
| Agent | Principal toxicity | Monitoring | Prevention and notes |
|---|---|---|---|
| ICI (pembrolizumab, nivolumab, ipilimumab) | Myocarditis (0.1–1.1%, fatality 25–50%), pericarditis, vasculitis, ventricular arrhythmia, Takotsubo, non-inflammatory LV dysfunction, ACS, dyslipidaemia (OR 3.68) | Baseline ECG + cTn + NP in all (I/B) and TTE in high risk (I/B); serial ECG + cTn before cycles 2, 3 and 4, then every 3 cycles if normal (IIa/B); CV assessment every 6–12 months beyond 12 months of therapy (I/C); any new cTn rise → urgent cardio-oncology review with TTE and CMR | |
| CAR-T / TIL | CRS-driven arrhythmia (77.6%), HF (14.3%), MI/VTE (~0.5%) | Baseline ECG + NP + cTn (I/C) and TTE if pre-existing CVD (I/C); NP + cTn + TTE at CRS grade ≥2 (I/C) | Tocilizumab ± dexamethasone for CRS |
| HSCT | HF, arterial events, cardiac tamponade, atrial and supraventricular arrhythmia; GVHD adds thrombosis, myocarditis and conduction disease | Baseline TTE (I/C) + NP (IIa/C) + CV risk assessment; TTE at 3 and 12 months in high-risk recipients |
Drug profiles — endocrine and androgen-directed therapy
CV event rates are from the AHA 2021 hormonal therapy statement and the ESC guideline; monitoring follows the ESC guideline (sources/Hormonal-Rx-AHA-2021, rating: high).
| Agent | Principal toxicity | Monitoring | Notes |
|---|---|---|---|
| Aromatase inhibitors (anastrozole, letrozole, exemestane) | Dyslipidaemia, accelerated atherosclerosis, HF; pooled RR 1.19 vs tamoxifen for CVD; 30% higher MI risk; OR 1.18 when extended beyond 5 years | Serial lipid profile, baseline CV risk assessment, GLS on echocardiography | |
| Tamoxifen | VTE +41% vs aromatase inhibitors; arterial CVD lower than placebo (pooled RR 0.67); toremifene and high-dose tamoxifen prolong QTc | Baseline CV risk assessment | Avoid with pre-existing thrombotic risk factors |
| CDK4/6 combinations | Ribociclib + AI or fulvestrant: QTc >480 ms in 3.3–5.6%; ribociclib + tamoxifen >5% (MONALEESA-7) — avoid this combination; palbociclib + AI: hypertension 6%; abemaciclib: no significant CV effect | Baseline ECG; QTc at day 14 and day 28 | |
| mTOR inhibitors (everolimus + exemestane) | Metabolic syndrome in >30% (BOLERO-2), especially with type 2 diabetes | Lipid profile, HbA1c, BP | |
| PI3K inhibitors (alpelisib + fulvestrant; copanlisib) | Grade 3 hyperglycaemia 36.6% vs 0.7% placebo (SOLAR-1); copanlisib commonly | Glucose monitoring and hyperglycaemia management | |
| ADT — GnRH agonists | Diabetes +44%, CAD +16%, MI +11%, sudden cardiac death +16% | SCORE2/SCORE2-OP, lipids, BMI and waist-to-hip ratio, HbA1c, BP | |
| ADT — GnRH antagonists | Fewer major CV events than agonists: HERO 2.9% vs 6.2% (HR 0.46); pooled 6 RCTs HR 0.44 | As agonists | Preferred in men with pre-existing symptomatic CAD (IIa/B) |
| AR-directed therapy (abiraterone, enzalutamide) | RR 1.36 (95% CI 1.13–1.64) for adverse CV events; ≥3 CV comorbidities → 1.56× all-cause mortality | AHA secondary prevention for men with established CVD |
Full breast and prostate cancer detail, including the ABCDE cardioprotection algorithm: concepts/Hormonal-Therapy-CV-Risk.
Practical thresholds and drug interactions
- Drug–drug interaction risk in this population is amplified by narrow therapeutic indices, polypharmacy and wide interpatient variability in metabolism. CYP3A4 is the dominant enzyme and P-glycoprotein the dominant transporter, so combinations must be checked drug by drug rather than by class (sources/cardio-oncology-drug-aha-2022, rating: very high).
- Ibrutinib: diltiazem, verapamil, amiodarone and dronedarone each raise ibrutinib exposure 6–9-fold through CYP3A4 inhibition and should be avoided; dabigatran is contraindicated through P-glycoprotein inhibition; factor Xa inhibitors interact moderately but are the preferred anticoagulant class (sources/cancer-rx-cv-acc-2025, rating: very high).
- DOACs: apixaban and rivaroxaban are dual CYP3A4 and P-gp substrates and are the most interaction-prone; edoxaban carries the least interaction risk. There is no validated routine assay for DOAC monitoring (sources/cardio-oncology-drug-aha-2022).
- Cardiovascular CYP3A4 inhibitors: diltiazem and verapamil significantly raise many TKI concentrations; when a strong inhibitor is unavoidable, switch simvastatin or lovastatin to pravastatin or rosuvastatin (sources/cardio-oncology-drug-aha-2022).
- Digoxin: anthracyclines reduce digoxin absorption by about 50% through P-gp induction and intestinal epithelial toxicity — monitor levels; liposomal formulations cause less induction (sources/cardio-oncology-drug-aha-2022).
- VEGF inhibitor hypertension (ACC 2025): target <130/80 mmHg irrespective of cardiovascular risk; start two antihypertensives immediately if BP is ≥160/100; withhold the VEGF inhibitor if BP is ≥180/110 until <160/100, then resume (sources/cancer-rx-cv-acc-2025).
- Ribociclib: interrupt if QTcF >480 ms and dose-reduce if ≥481 ms recurs; avoid strong CYP3A inhibitors and tamoxifen.
- Antithrombotic thresholds in thrombocytopenia: aspirin >10,000/µL, clopidogrel >30,000/µL, prasugrel and ticagrelor >50,000/µL.
- Radiotherapy risk bands by mean heart dose: very high >25 Gy, high 15–25 Gy, moderate 5–15 Gy, low <5 Gy (sources/Cardio-Oncology-ESC-2022, rating: very high).
Mechanisms — vascular toxicity of traditional chemotherapy
From the 2019 AHA vascular cardio-oncology statement (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high).
| Agent | Vascular mechanism | Key vascular toxicities |
|---|---|---|
| Fluoropyrimidines (5-FU, capecitabine) | Endothelial injury; ↑ endothelin-1; vasospasm | Coronary vasospasm (up to 5.4% with continuous 5-FU); Raynaud |
| Taxanes | Cytoskeletal disruption of endothelial and smooth muscle cells | Capillary leak and fluid retention; peripheral neuropathy (vasa nervorum); myocardial ischaemia |
| Vinca alkaloids (vincristine, vinblastine) | Caspase-mediated apoptosis; ↓ endothelial cell proliferation | Chest pain, MI, hypertension, Raynaud, thromboembolism |
| Platinum compounds (cisplatin) | Direct endothelial toxicity; ↑ platelet aggregation; ↓ NO | Raynaud, hypertension, MI, stroke, arterial thrombosis, acute limb ischaemia, DVT/PE |
| Cyclophosphamide | As platinums; ↓ ACE activity | Hypertension, MI, cerebrovascular events, hepatic veno-occlusive disease, PAH, Raynaud |
| Anthracyclines | ROS, DNA double-strand breaks, mitochondrial dysfunction, endothelial injury | Endothelial dysfunction persisting months to years; clinically under-studied |
| Bleomycin | ↓ endothelial proliferation and migration; endothelial apoptosis | Raynaud (3× risk in testicular cancer, dose-related); MI; PAH |
Mechanisms — VEGF inhibitor hypertension and metabolic effects
From the 2019 AHA statement (sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high).
- Hypertension mechanisms: reduced eNOS activity and NO bioavailability; increased endothelin-1; capillary rarefaction raising microcirculatory resistance; and a rightward shift of the renal pressure-natriuresis curve causing sodium retention and salt-dependent hypertension.
- Cardiomyopathy mechanism: capillary rarefaction causes myocardial hypoxia and HIF stabilisation, producing a reversible cardiomyopathy consistent with hibernation rather than necrosis.
- Preeclampsia parallel: sFlt-1, a soluble VEGF decoy receptor secreted by the placenta, may mediate preeclampsia through the same pathway — an on-target rather than off-target effect of VEGF inhibition.
- Metabolic effects cross-cut class boundaries: VEGF and PDGF TKIs (sunitinib, sorafenib) improve glycaemia, and within the BCR-ABL class imatinib improves glycaemia while nilotinib worsens it — opposite effects from the same target, reflecting off-target kinase effects on metabolism.
- ADT metabolic effects reverse on cessation and endothelial function is paradoxically preserved; randomised oncology trial data show increased mortality only in men with pre-existing CAD or HF, which is why the GnRH antagonist signal matters most in that group.
Topics on dedicated pages
- Arrhythmias — AF is the commonest (2–16% during active treatment); ibrutinib carries the highest burden of any targeted agent (RR 4.69, meta-analysis of 8 RCTs, n=2,580) and newer BTK inhibitors are safer alternatives. ICI-associated AV block may be the first manifestation of myocarditis. Standard risk scores fail: CHA₂DS₂-VASc underestimates thromboembolism and HAS-BLED cannot capture thrombocytopenia or brain metastases, and DOACs are preferred over aspirin. See concepts/Cancer-Associated-Arrhythmia (sources/arrhythmia-cardio-oncology-aha-2021, rating: very high).
- Autonomic dysfunction — reduced heart rate variability, orthostatic hypotension, inappropriate sinus tachycardia and POTS are prevalent in survivors, particularly after haematological malignancy, and are associated with mortality; structured aerobic exercise reverses it and ivabradine is a candidate for inappropriate sinus tachycardia. See concepts/Autonomic-Dysfunction-in-Cancer.
- Therapy-related clonal haematopoiesis — cytotoxic therapy and radiation select DNA damage response variants (TP53, PPM1D, CHEK2, ATM) in up to 30% of relatively young survivors; TP53 clones are amplified by doxorubicin and worsen anthracycline cardiomyopathy, and PPM1D clones drive myocardial fibrosis through IL-1β and the NLRP3 inflammasome. See concepts/Clonal-Hematopoiesis (sources/ch-aha-2026, rating: very high).
- Multi-omics and AI — TTNtv and RARG variants in anthracycline cardiotoxicity, α-myosin-specific T-cell populations in ICI myocarditis, hemopexin as an anthracycline biomarker and early TCA-cycle changes preceding LVEF decline are all research-stage; AI-ECG detects LV dysfunction and arrhythmic risk, but no model has been prospectively validated. See concepts/AI-in-Cardio-Oncology (sources/ai-cardiooncology-aha-2025, rating: high).
Contradictions / Open Questions
- Most recommendations rest on Level of Evidence C. Dedicated cardio-oncology randomised trials are scarce, and much of the evidence base is small trials, subgroup analyses and registry data (sources/Cardio-Oncology-ESC-2022, rating: very high).
- The optimal timing and duration of cardioprotective medication is unknown. Neither when to start ACE-I or beta-blockade nor how long to continue it after cancer therapy has been established by RCT (sources/Cardio-Oncology-ESC-2022).
- Prophylactic versus triggered cardioprotection is unresolved: whether to treat all high-risk patients from the outset or only when subclinical CTRCD is detected (sources/Cardio-Oncology-ESC-2022).
- The optimal ICI myocarditis immunosuppression regimen and duration are undefined, and the evidence for second-line agents is largely case series. Infliximab is cautioned against despite being standard second-line treatment in other inflammatory diseases (sources/cancer-rx-cv-acc-2025).
- Fluoropyrimidine rechallenge after vasospasm has no RCT support — only case series using prophylactic nitrates and CCBs in a monitored setting (sources/Cardio-Oncology-ESC-2022).
- GnRH antagonist versus agonist benefit is contested: HERO suggests fewer CV events with antagonists, while PRONOUNCE found no MACE difference — although PRONOUNCE stopped early and both arms received optimal risk factor management (sources/Hormonal-Rx-AHA-2021).
- HFA-ICOS is retrospective. The tool has not been prospectively validated in large RCTs, and its applicability across cancer types outside those used to build it is uncertain (sources/Cardio-Oncology-ESC-2022).
- Biomarker-guided cardioprotection has not been shown superior: troponin-guided enalapril did not beat universal enalapril (n=276), and hsTnI-guided candesartan/carvedilol did not prevent LV dysfunction, though both trials were small with low event rates (sources/ai-cardiooncology-aha-2025, rating: high).
- SUCCOUR's negative result may be an endpoint artefact. Strain-guided therapy failed on a 2D LVEF endpoint that is probably insensitive, and clinical HF events were not reported, so GLS remains most useful when LVEF is low-normal (sources/imaging-cardio-oncology-aha-2024, rating: high).
- LVEF is inadequate for several toxicities. It does not detect ICI myocarditis, where it is normal in up to half of cases, or targeted-therapy arrhythmias; T1/T2 mapping and GLS add sensitivity but lack prospective validation against clinical endpoints, and the role of ⁶⁸Ga-DOTATOC and FAPI PET in ICI myocarditis remains undefined (sources/imaging-cardio-oncology-aha-2024).
Connections
Cardio-oncology domain
- concepts/Cardio-Oncology — the discipline and care-pathway overview
Toxicity domains with dedicated pages
- concepts/HFA-ICOS-Risk-Stratification — full scoring by treatment category
- concepts/Cancer-Associated-Arrhythmia — AF, QT prolongation, ventricular arrhythmia and anticoagulation
- concepts/Autonomic-Dysfunction-in-Cancer — HRV, orthostatic intolerance, IST and POTS
- concepts/Hormonal-Therapy-CV-Risk — endocrine and androgen-directed therapy in detail
- concepts/Cancer-Associated-VTE — the commonest cardiovascular complication of malignancy
- concepts/Clonal-Hematopoiesis — CHIP and therapy-related CH as shared cancer–CVD risk
- concepts/AI-in-Cardio-Oncology — multi-omics, AI-ECG and risk models
- concepts/Radiation-Vasculopathy — radiation-induced arterial disease
- concepts/Cardiac-Amyloidosis-Imaging — ⁹⁹mTc-PYP and CMR for ATTR
- concepts/Late-Gadolinium-Enhancement — the CMR finding underlying myocarditis and scar assessment
Clinical entities
- entities/Heart-Failure — the phenotype of CTRCD and the target of HF therapy
- entities/Atrial-Fibrillation — the commonest arrhythmia during cancer treatment
- entities/DCM — anthracycline cardiomyopathy overlaps with dilated cardiomyopathy
- entities/ATTR-Amyloidosis — relevant to ⁹⁹mTc-PYP imaging in cancer patients
Sources
Guidelines and clinical guidance
Imaging, biomarkers and AI
Vascular, metabolic and hormonal toxicity
Drug interactions
Arrhythmia and clonal haematopoiesis